Opposed to the current heparin production method, our technology has the potential to ensure supply security, reduce risk of contamination and remove dependency on animal material.

We created a method of projecting a surgical planning onto the patient. This way the surgeon spends less time on preparation (20 min) and performs surgeries faster (19 min). The prototype is in continuous use in Radboudumc (400+ surgeries).

Optimal delivery to ensure effective treatment of cancer and more

Fenix Therapeutics aims to reshape cancer outcomes, providing hope to patients by transforming the future of oncology through more specific and effective treatments.

Personalized targeted treatment selection for metastatic cancer patients through full blood volume tumor cell analysis.

Gemini Theranostics developed a theranostic platform targeting the Follicle Stimulating Hormone Receptor (FSHR), a therapeutic target that is expressed in 50-70% of ovarian cancer patients.

Next-generation gene promoters for more stable and higher recombinant protein expression.

Pionering whole genome sequencing based genotoxicity testing

GlycoCheck measures and analyzes microvascular health, and objectively reports a MicroVascular Health Score (MVHS)

A robust patient monitoring device which is highly reliable and easy to use to prevent children in low and middle income countries unnecessary dying from severe bacterial infections.